Search

Search Results

• The macroeconomic possibilities of biosimilars in developed countries

  3-18

  Peter Halmosi

  Views:

  182

  Biosimilars have been used for the treatment of chronic diseases since 2006 in the EU but only since 2015 in the U.S. Despite high market potentials and presumed positive macroeconomic effects in the health care sector, widespread usage is strongly confronted with the opposition of physicians and pharmacists. However, biosimilars are supposed to reform health care financing, alter market positions of pharmaceutical companies and amend informational triangle among physicians, patients and insurance companies in the near future. The use of biosimilars is supposed by experts to reach extra health related savings even if doctors and pharmacists are averse to offer these products to patients in a certain therapeutic area. Governments have currently found no unique way of regulating the marketing, substitution and price regulation of biosimilars. The aim of this study is to discuss the macroeconomic possibilities and barriers incarnated in the usage of biosimilars in developed countries.

  Journal of Economic Literature (JEL) codes: H51, I11, I12, J18